REBIF SUMMARY
REBIF (interferon beta-1a) is a purified 166 amino acid glycoprotein with a molecular weight of approximately 22,500 daltons.
REBIF (interferon beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Rebif (Interferon Beta-1A)
Cognitive dysfunction in patients with multiple sclerosis treated with different
types of interferon beta: a randomized clinical trial. [2014]
function in MS... CONCLUSIONS: Different types of DMTs may improve some aspects of cognitive
Neutralizing antibodies in multiple sclerosis patients on weekly intramuscular
Avonex and biosimilar interferon beta-1a (CinnoVex): comparing results of
measurements in two different laboratories. [2013]
The appearance of neutralizing antibodies (NAbs) has significant clinical and
regulatory consequences for interferons in patients with multiple sclerosis (MS). In a double blind, randomized clinical trial, 84 patients with relapsing
remitting MS were enrolled in a 24month study period... As similar
results were obtained from CinnoVex or Avonex in our study, we suggest that both
medications will have a similar immunogenetic profile.
Comparing efficacy and side effects of a weekly intramuscular
biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting
multiple sclerosis: a double blind randomized clinical trial. [2012]
USA) and CinnoVex (CinnaGen, Iran)... CONCLUSION: CinnoVex can be used as a safe and effective alternative to Avonex in
Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year
follow-up of the ASA cohort. [2012]
combined with low-dose azathioprine and prednisone in multiple sclerosis... CONCLUSION: The tested combined therapeutic regimen does not improve long-term
Interferon beta for secondary progressive multiple sclerosis. [2012]
CONCLUSIONS: Well designed RCTs, evaluating a high number of patients
Clinical Trials Related to Rebif (Interferon Beta-1A)
Supplementation of VigantOL� Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif� Treatment [Completed]
The drug being tested is called VigantOL® oil - a very effective form of Vitamin D hormone
supplement (cholecalciferol). Low levels of Vitamin D have been described to be associated
with a higher risk of developing Multiple Sclerosis (MS), and it is known that up to 90% of
patients with Multiple Sclerosis have Vitamin D deficiency.
Rebif® is known to be an effective treatment for slowing down the progression of MS. The
purpose of this research trial is to evaluate if VigantOL® oil on top of Rebif® has any
benefit on the progression of MS compared to Rebif® and placebo.
Disease activity will be assessed by clinical examination and Magnetic Resonance Imaging
(MRI). The planned study treatment duration for each study participant is 48 weeks, and the
study consists of a total of 8 visits. Study participants who are already passed Week 48 at
the time of approval of Protocol Amendment 5 will have a study duration of 96 weeks and a
total of 12 visits.
During the study, the participant will undergo physical examination, neurological
assessments, safety assessments, blood tests and urinalysis (including pregnancy tests).
Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif� New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. [Completed]
This observational multicentric study is planned to assess the tolerability of Rebif New
Formulation in an Australian clinical setting by the incidence of injection site reactions
(ISRs). The study will allow the comparison of tolerability data with historical data for
both Rebif New and classic formulations, and will do so by using the same pre- specified
preferred terms of treatment emergent adverse events as done in historical studies. In
addition, the study will analyse whether interaction(s) with a nurse impacts tolerability
and the impact of Rebif New Formulation on the patient's Quality of Life.
An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis [Completed]
The aim of this case series was to document the effectiveness and compatibility of Rebif 44
or 22 µg in the therapy of the chronic multiple sclerosis (MS) under practical conditions on
a large collection of subjects. In addition, the side effects possibly occurring in the
initial phase of therapy and satisfaction of the subject as well as the treating doctor was
also documented.
Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® [Completed]
The study is planned to evaluate the cognitive functions in subjects with RRMS treated with
interferon beta-1a, and its relationship to the fatigue and neurological dysfunction status.
Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY) [Completed]
The aim of this retrospective study is to review and describe safety, tolerability and
efficacy of Rebif® (subcutaneous interferon [IFN]-beta-1a) in children and adolescents,
using information already recorded in medical records. The study duration is 13 July 2010
(first data collected) to 13 July 2011 (last data collected). In this study, Data of the
subjects evaluated between 1997 and 2009 was observed.
Reports of Suspected Rebif (Interferon Beta-1A) Side Effects
Injection Site Erythema (716),
Multiple Sclerosis Relapse (680),
Injection Site Pain (519),
Influenza Like Illness (489),
Fall (424),
Fatigue (364),
Headache (363),
Injection Site Haematoma (335),
Pain (268),
Depression (265), more >>
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Rebif has an overall score of 6. The effectiveness score is 8 and the side effect score is 6. The scores are on ten point scale: 10 - best, 1 - worst.
| | Rebif review by 29 year old female patient | | | Rating |
| Overall rating: | |   |
| Effectiveness: | | Considerably Effective |
| Side effects: | | Moderate Side Effects | | |
Treatment Info |
| Condition / reason: | | Multiple Sclerosis |
| Dosage & duration: | | 250 mg taken 3x weekly for the period of 18 months |
| Other conditions: | | none |
| Other drugs taken: | | none | | |
Reported Results |
| Benefits: | | Reduce number of MS relapses |
| Side effects: | | Flu like symptoms- aches, fever |
| Comments: | | subcutaneous injection 3x weekly |
|
|
|
Page last updated: 2015-08-10
|
